Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis (Q43770234)

26 November 2017

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis (English)

1 reference

26 November 2017

1 reference

12

Wafaa El-Sadr

1 reference

26 November 2017

William Burman

1

1 reference

26 November 2017

Debra Benator

2

1 reference

26 November 2017

Andrew Vernon

3

1 reference

26 November 2017

Awal Khan

4

1 reference

26 November 2017

Brenda Jones

5

1 reference

26 November 2017

Claudia Silva

6

1 reference

26 November 2017

Chris Lahart

7

1 reference

26 November 2017

Stephen Weis

8

1 reference

26 November 2017

Barbara King

9

1 reference

26 November 2017

Bonita Mangura

10

1 reference

26 November 2017

Marc Weiner

11

1 reference

26 November 2017

Tuberculosis Trials Consortium

13

1 reference

26 November 2017

language of work or name

English

0 references

publication date

18 August 2005

1 reference

American Journal of Respiratory and Critical Care Medicine

26 November 2017

1 reference

26 November 2017

173

1 reference

26 November 2017

3

1 reference

26 November 2017

350-356

1 reference

Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus.

26 November 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clini

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Evaluation of the epidemiologic utility of secondary typing methods for differentiation of Mycobacterium tuberculosis isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

The rpoB gene of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Regression modelling strategies for improved prognostic prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

Regional differences in presentation of AIDS in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200503-417OC

10.1164/RCCM.200503-417OC

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference